Nowadays we use novel diagnostic equipment for lung cancer. Bronchoscopy was the tip of the arrow for diagnosis, however; ultrasound systems have brought a revolution. We have the radial-endobronchial ultrasound for peripheral lesions and the convex probe endobronchial ultrasound for central lesions. Ultrasound endoscopic systems can be used for the diagnosis of any lesion that can be approached from the airways. In the current manuscript we will present two methods for the biopsy of thyroid gland. The first method is using anesthisiological tools and the second tools from the ear, nose and throat department.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925947 | PMC |
| http://dx.doi.org/10.1016/j.rmcr.2018.01.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Iatrogenic intramural esophageal hematoma during EUS-B-FNA procedure.
BMC Pulm Med
January 2025
Unidade de Broncologia e Pneumologia de Intervenção - Instituto Português de Oncologia Francisco Gentil, Coimbra, Portugal.
Background: Esophageal ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is a valuable tool for the diagnosis and staging of lung cancer, complementing endobronchial lung ultrasound (EBUS). While generally considered safe, there is a notable lack of comprehensive knowledge within the interventional pulmonology community regarding potential complications.
Case Presentation: We present a case involving a 66-year-old male with squamous cell lung carcinoma undergoing mediastinal staging.
Pulmonary tuberculosis presenting as a hilar mass.
BMJ Case Rep
January 2025
Pulmonary Medicine, Siksha O Anusandhan University Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Orissa, India.
Tuberculosis (TB) is a great mimicker due to its various unusual and atypical presentations. Mass-like lesions in thoracic radiology may raise the suspicion of lung malignancy. A man in his early 50s complained of cough, low-grade fever and dyspnoea.
View Article and Find Full Text PDFRadiological and Pathological Analysis of Pembrolizumab-Associated Lung Lesions: Diagnostic Challenges and Management.
Am J Case Rep
January 2025
Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Mie, Japan.
BACKGROUND Pembrolizumab, a programmed cell-death protein-1 (PD-1)-targeting antibody, extends survival in cancer patients but may cause lung injury as a side effect. This immunotherapy enhances the immune system's ability to recognize and eliminate cancer cells. However, its immunomodulatory action can sometimes lead to immune-related adverse events, including lung injury.
View Article and Find Full Text PDFRobotic bronchoscopy: Evolution of advanced diagnostic technologies for pulmonary lesions.
Best Pract Res Clin Anaesthesiol
March 2024
1400 Holcombe Blvd, FC 13.2000, Houston, TX, 77030, USA. Electronic address:
Lung cancer is among one of the most commonly diagnosed malignancies and is the leading cause of cancer-related mortality in both men and women globally, with an estimated 1.8 million deaths annually. Moreover, it is also the leading cause of cancer related deaths in the United States (U.
View Article and Find Full Text PDFDiagnostic and Management Challenges in Interferon-γ Release Assay-Positive Patient with Sarcoid Panuveitis from a Non-Endemic Tuberculosis Region.
Ocul Immunol Inflamm
January 2025
Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Purpose: To report a case of biopsy-proven sarcoidosis in a patient with panuveitis and a positive interferon-gamma release assay (IGRA) from a non-endemic tuberculosis (TB) country.
Methods: Case report.
Results: A 26-year-old male from the United Arab Emirates (UAE) presented with granulomatous panuveitis characterized by mutton-fat keratic precipitates, anterior chamber and vitreous cells, and retinal vasculitis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!